Dr. Zoran Kurepa, M.D., PH.D.
What this data tells you about Dr. Kurepa
Dr. Zoran Kurepa is an internal medicine specialist in Dallas, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Kurepa performed 132,432 Medicare services across 2,917 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kurepa received a total of $589,731 from 41 pharmaceutical and/or device companies across 1755 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kurepa is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) | 80,400 | $4 | $15 |
| Romosozumab injection (Evenity) for osteoporosis | 15,330 | $8 | $39 |
| Denosumab injection (Prolia/Xgeva) | 14,760 | $18 | $69 |
| Inclisiran injection (Leqvio) for cholesterol | 5,396 | $9 | $53 |
| Golimumab infusion (Simponi Aria) | 4,450 | $10 | $145 |
| Abatacept infusion (Orencia) | 3,775 | $34 | $256 |
| Infliximab infusion (Remicade) | 2,970 | $27 | $404 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 710 | $56 | $224 |
| Office visit, established patient (30-39 min) | 666 | $89 | $378 |
| Comprehensive metabolic blood panel | 477 | $10 | $32 |
| Complete blood count (CBC) with differential | 424 | $7 | $23 |
| Creatine kinase (cardiac enzyme) level, total | 421 | $6 | $20 |
| Blood draw (venipuncture) | 416 | $8 | $27 |
| C-reactive protein test (inflammation marker) | 400 | $5 | $16 |
| Sed rate test (inflammation marker) | 397 | $3 | $8 |
| Urinalysis with microscopic exam | 166 | $3 | $10 |
| Automated urinalysis | 149 | $2 | $7 |
| Administration of chemotherapy into vein, 1 hour or less | 149 | $102 | $3,036 |
| Drug injection, under skin or into muscle | 117 | $11 | $506 |
| New patient office visit, complex (60-74 min) | 99 | $158 | $648 |
| Vitamin D level test | 86 | $29 | $89 |
| Administration of chemotherapy into vein, each additional hour | 57 | $22 | $635 |
| Measurement of complement (immune system proteins), antigen, | 56 | $11 | $36 |
| Uric acid level test | 55 | $4 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 45 | $44 | $1,505 |
| Flu vaccine administration | 45 | $31 | $80 |
| Joint injection, major joint | 44 | $52 | $191 |
| Measurement of antibody for rheumatoid arthritis assessment | 43 | $12 | $39 |
| Flu vaccine, high-dose | 43 | $72 | $587 |
| Rheumatoid factor level | 42 | $5 | $17 |
| Measurement of antibody for assessment of autoimmune disorder, any method | 34 | $17 | $54 |
| Injection, methylprednisolone acetate, 80 mg | 31 | $9 | $37 |
| Injection of additional new drug or substance into vein | 28 | $12 | $435 |
| Screening test for autoimmune disorder | 27 | $11 | $36 |
| Screening test for antibody to noninfectious agent | 25 | $11 | $36 |
| Hepatitis b core antibody measurement | 20 | $12 | $36 |
| Hepatitis b surface antibody measurement | 20 | $11 | $32 |
| Hepatitis c antibody measurement | 20 | $14 | $43 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 20 | $10 | $31 |
| Office visit, established patient, complex (40-54 min) | 19 | $133 | $530 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in internal medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for internal medicine in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kurepa is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), with speaking/promotional industry engagement in the top 0% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kurepa experienced with certolizumab injection (cimzia)?
Does Dr. Kurepa receive payments from pharmaceutical companies?
How do Dr. Kurepa's costs compare to other internal medicine physicians in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology